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ABSTRACT
Objective: Zinc deficiency is widespread, and
preventive supplementation may have benefits in young
children. Effects for children over 5 years of age, and
effects when coadministered with other micronutrients
are uncertain. These are obstacles to scale-up. This
review seeks to determine if preventive
supplementation reduces mortality and morbidity for
children aged 6 months to 12 years.
Design: Systematic review conducted with the
Cochrane Developmental, Psychosocial and Learning
Problems Group. Two reviewers independently
assessed studies. Meta-analyses were performed for
mortality, illness and side effects.
Data sources: We searched multiple databases,
including CENTRAL and MEDLINE in January 2013.
Authors were contacted for missing information.
Eligibility criteria for selecting studies:
Randomised trials of preventive zinc supplementation.
Hospitalised children and children with chronic
diseases were excluded.
Results: 80 randomised trials with 205 401
participants were included. There was a small but
non-significant effect on all-cause mortality (risk ratio
(RR) 0.95 (95% CI 0.86 to 1.05)). Supplementation
may reduce incidence of all-cause diarrhoea (RR 0.87
(0.85 to 0.89)), but there was evidence of reporting
bias. There was no evidence of an effect of incidence
or prevalence of respiratory infections or malaria. There
was moderate quality evidence of a very small effect on
linear growth (standardised mean difference 0.09 (0.06
to 0.13)) and an increase in vomiting (RR 1.29 (1.14 to
1.46)). There was no evidence of an effect on iron
status. Comparing zinc with and without iron
cosupplementation and direct comparisons of zinc plus
iron versus zinc administered alone favoured
cointervention for some outcomes and zinc alone for
other outcomes. Effects may be larger for children over
1 year of age, but most differences were not significant.
Conclusions: Benefits of preventive zinc
supplementation may outweigh any potentially adverse
effects in areas where risk of zinc deficiency is high.
Further research should determine optimal intervention
characteristics and delivery strategies.
INTRODUCTION
Regular dietary zinc intake is required
because zinc cannot be produced or
stored.
12In 2011, 116 000 deaths in children
under 5 years were attributable to zinc deﬁ-
ciency (1.7% of mortalities in this group).
3
Previous reviews have reached disparate
conclusions about the beneﬁts of zinc sup-
plementation for young children,
4–12 and
most have not examined evidence for chil-
dren over 5 years of age. Zinc deﬁciency is
prevalent in areas with other micronutrient
deﬁciencies. Concerns about the administra-
tion of zinc with iron have been an obstacle
to widespread delivery.
13 Understanding the
effects of preventive zinc supplementation
alone and with iron is crucially important to
the future of global health policy.
To evaluate the effects of zinc with or
without iron on illness and mortality, as well
as growth, we analysed direct comparisons
(ie, zinc plus iron vs zinc alone) as well as
subgroups within an overall analysis.
METHODS
Selection criteria and search strategy
Following a published protocol,
14 we con-
ducted a systematic review of randomised
clinical trials of orally administered zinc com-
pared with placebo and non-zinc cointerven-
tions received by both groups (eg, vitamin
A). We also compared zinc with and without
iron cosupplementation. Participants were
6 months to 12 years of age. We excluded
Strengths and limitations of this study
▪ This large review was conducted according to
best practices and includes the highest quality
current evidence about the effects of zinc
supplementation.
▪ We investigated several outcomes and made
multiple comparisons to explore the most
important main effects and interactions.
▪ The analyses in this review could not identify the
best way to deliver zinc supplements to children
in need.
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acutely ill.
We searched the African Index Medicus, CENTRAL,
Conference Proceedings Citation Index, EMBASE,
Global Health, ICTRP, IndMED, LILACS, MEDLINE,
metaRegister of Controlled Trials, ProQuest Dissertations
& Theses Database and WHOLIS in December 2012 and
January 2013 (see online supplementary appendix 1).
Reference lists from previous reviews and from included
studies were examined, and trial authors were contacted
for unpublished data. Two authors independently
reviewed citations and extracted data, including partici-
pant demographics, details of the intervention, out-
comes and risk of bias.
15
Data synthesis
Relative risks and 95% CIs were calculated using
Mantel-Haenszel methods. Standardised mean differ-
ences (SMDs) and 95% CIs were calculated for continu-
ous measures using Hedges g and combined using
inverse variance methods. When studies reported data
in multiple formats, we calculated the SMD and its SE in
Comprehensive Meta-Analysis (CMA) V.2 before enter-
ing data in Review Manager (RevMan) V.5.2. For inci-
dence data, we combined risk ratios (RR) (events per
child) and rate ratios (events per child year) because
trials were relatively short and we did not anticipate
interactions between the intervention and time at risk.
For cluster-randomised trials, we used effects controlling
for clustering, or we used a intracluster correlation coef-
ﬁcient to estimate robust SEs.
15 We used ﬁxed-effect
methods for all meta-analyses. Effects favour interven-
tion when the relative risk is reduced (RR<1) or the
standardised difference is positive (SMD>0).
When 10 or more studies reported an outcome, we
conducted subgroup analyses to explore the effects of
iron cosupplementation, national income (low-income
countries compared with others), stunting, age (6–12,
more than 12 months), dose (0–5, 5–10 mg, etc), dur-
ation (0–6, 6–12, more than 12 months) and
formulation.
Quality of the evidence
Quality of the evidence was judged independently using
GRADE.
16 The GRADE system rates evidence from each
analysis (ie, pooled data where possible) as ‘high’, ‘mod-
erate’, ‘low’ or ‘very low’.A‘high’ rating suggests that
evidence is unlikely to be affected by further studies; a
‘low’ rating suggests that further research is required to
conﬁrm the direction and magnitude of the true effect.
Ratings for meta-analyses of randomised controlled trials
start at ‘high’ and may be downgraded for threats
to internal validity (ie, within-study bias), inconsistency
(ie, heterogeneity in results across studies), indirectness
(eg, measures are proxies for the true outcome of inter-
est), imprecision (eg, few participants, wide CIs) and
reporting bias (ie, publication bias and selective
outcome reporting). Because GRADE considers several
domains in addition to internal validity, conﬁdence in
overall effects may be ‘low’ or ‘very low’ even when all
studies are conducted rigorously. The following sections
include signiﬁcant and non-signiﬁcant statistical results,
and GRADE ratings in the text and tables provide
further information about our conﬁdence in these
estimates.
RESULTS
Results of the search
From 6384 records, 80 studies were included (ﬁgure 1).
Seventy-ﬁve studies were published in English, two each
in Spanish and Portuguese and one in Chinese. Reasons
for excluding 27 studies were enumerated (see online
supplementary appendix 2); additionally, 11 ongoing
studies were identiﬁed, and 5 studies could not be
obtained. Seven included studies did not contribute to
any meta-analysis because they did not report sufﬁcient
data (see online supplementary appendix 3).
Study characteristics
Included studies assigned 205 923 eligible participants
(see online supplementary appendix 4). Twenty trials
used factorial designs; there were 100 independent com-
parisons isolating zinc, and cointerventions were pro-
vided to both groups in 51 comparisons. There were
eight independent comparisons of iron with zinc versus
zinc alone including 1898 eligible participants. Sample
sizes ranged from 21 to 72 438 eligible participants
(median=200). Nine studies were cluster-randomised,
including two randomising households. Three studies
included 88% of participants.
17–19 Forty-six studies
reported the mean baseline plasma or serum zinc con-
centration of their participants; the median of these
mean concentrations was 72.5 μg/dL.
Thirty-two countries are represented; most studies
were conducted in low-income or middle-income coun-
tries: 37 in Asia, 26 in Latin America and the Caribbean
and 10 in sub-Saharan Africa. The median of mean age
at baseline was 28 months, and 22 studies included chil-
dren over 5 years of age. Stunted and non-stunted chil-
dren were included in 42 studies; 5 included only
stunted children, 5 included only non-stunted children
and 28 did not specify if participants were stunted.
Studies provided zinc for less than 6 (30), 6–12 (33)
and 12 months or more (16). Of those reporting fre-
quency of zinc supplementation, 48 provided zinc daily
and 11 provided zinc weekly. Where reported, daily dose
was 0–5 (5), 5–10 (19), 10–15 (30), 15–20 (8) and
20 mg or more (12). Studies reporting the chemical
compound of their zinc supplements provided zinc as
sulfate (45), gluconate (12), acetate (6) and other com-
pounds (8). Studies comparing zinc with iron versus
zinc alone provided daily dose equivalents of 3–36 mg of
iron. Outcomes were observed for about 26 weeks
(median) after randomisation, with follow-up from
2–80 weeks.
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Randomisation and allocation concealment were
adequate in 34 and 32 studies; 46 and 48 studies were
unclear (ﬁgure 2). For blinding of participants and per-
sonnel, 63 studies were at low risk of bias. For blinding
of outcome assessment, 65 studies were at low risk of
bias. For both types of blinding, 15 studies were unclear.
For all analyses, we attempted to include all rando-
mised study participants; 47 studies were at low risk of
bias for incomplete data, 31 were unclear and 2 were at
high risk. For selective reporting, 3 studies were at low
risk of bias, 44 were at unclear risk and 32 were at high
risk (see online supplementary appendix 5).
Bias may affect secondary outcomes in this review, but it
does not appear to be important for the primary outcome.
For example, mortality and other objective measures are
not vulnerable to bias related to blinding, and many
missing outcomes were biomarkers or growth related.
Figure 2 Risk of bias summary.
Figure 1 PRISMA flow chart.
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Outcomes
Illustrative comparative risks* (95% CI)
Relative effect (95% CI)
Number of participants
(studies)
Quality of the
evidence
(GRADE)
Assumed risk Corresponding risk
Control Zinc
All-cause mortality
Follow-up: 17–72 weeks
Low RR 0.95 (0.86 to 1.05) 138 302 (13 studies) ⊕⊕⊕⊕
High 2400/1 000 000 2280/1 000 000 (2064 to 2520)
High
34 900/1 000 000 33 155/1 000 000 (30 014 to 36 645)
Mortality due to
all-cause diarrhoea
Follow-up: 52–69 weeks
Low RR 0.95 (0.69 to 1.31) 132 321 (4 studies) ⊕⊕⊕⊝
Moderate† 800/1 000 000 760/1 000 000 (552 to 1048)
High
3000/1 000 000 2850/1 000 000 (2070 to 3930)
Mortality due to LRTI
Follow-up: 52–69 weeks
Low RR 0.86 (0.64 to 1.15) 132 063 (3 studies) ⊕⊕⊕⊝
Moderate† 1200/1 000 000 1032/1 000 000 (768 to 1380)
High
3000/1 000 000 2580/1 000 000 (1920 to 3450)
Mortality due to malaria
Follow-up: 46–69 weeks
Low RR 0.90 (0.77 to 1.06) 42 818 (2 studies) ⊕⊕⊕⊝
Moderate† 7400/1 000 000 6660/1 000 000 (5698 to 7844)
High
14 200/1 000 000 12 780/1 000 000 (10 934 to 15 052)
Incidence of all-cause
diarrhoea
Follow-up: 12–72 weeks
Low RR 0.87 (0.85 to 0.89) 15 042 (35 studies) ⊕⊕⊝⊝
Low‡§ 20 000/1 000 000 17 400/1 000 000 (17 000 to 17 800)
High
1 770 000/1 000 000 1 539 900/1 000 000 (1 504 500 to 1 575 300)
Incidence of LRTI
Follow-up: 12–52 weeks
Low RR 1.00 (0.94 to 1.07) 9610 (12 studies) ⊕⊕⊕⊕
High 30 000/1 000 000 30 000/1 000 000 (28 200 to 32 100)
High
370 000/1 000 000 370 000/1 000 000 (347 800 to 395 900)
Incidence of malaria
Follow-up: 24–47 weeks
Low RR 1.05 (0.95 to 1.15) 2407 (4 studies) ⊕⊕⊕⊝
Moderate¶ 140 000/1 000 000 147 000/1 000 000 (133 000 to 161 000)
High
2 950 000/1 000 000 3 097 500/1 000 000 (2 802 500 to 3 392 500)
Height
Follow-up: 10–60 weeks
The mean height in
the control groups was −1 HAZ
The mean height in the intervention
groups was 0.1 HAZ better (0 to 0.2 better)
SMD 0.09 (0.06 to 0.13) 13 669 (51 studies) ⊕⊕⊕⊝
Moderate**
Participants with one
vomiting episode
Follow-up: 24–52 weeks
Low RR 1.29 (1.14 to 1.46) 35 192 (4 studies) ⊕⊕⊕⊕
High 17 500/1 000 000 22 575/1 000 000 (19 950 to 25 550)
High
300 600/1 000 000 387 774/1 000 000 (342 684 to 438 876)
GRADE working group grades of evidence.
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
*The basis for the assumed risk (eg, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
†Few deaths were observed overall.
‡I
2=88%.
§Trim-and-fill analysis suggests that the effect may be overestimated due to publication bias.
¶I
2=44%.
**I
2=86%.
LRTI, lower respiratory tract infection; SMD, standardised mean difference.
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sEffects of zinc supplementation
In addition to outcomes included in the summary of
ﬁndings table (table 1), we analysed results for hospital-
isation; prevalence of morbidities; additional measures
of growth; as well as biological indicators of zinc, haemo-
globin, iron and copper status (table 2). Subgroup ana-
lyses compared the effects of zinc supplementation with
and without iron coadministration (table 3, see online
supplementary appendix 6).
Fourteen studies including 138 302 participants were
analysed for all-cause mortality, though other studies
included no deaths in either group (ﬁgure 3), and
there was high quality evidence of a small effect (risk
ratio 0.95 (0.86 to 1.05)). There were similar effects for
mortality due to diarrhoea (RR 0.95 (0.69 to 1.31)),
mortality due to lower respiratory tract infection (LRTI;
RR 0.86 (0.64 to 1.15)) and mortality due to malaria
(RR 0.90 (0.77 to 1.06)), and the evidence for these out-
comes was moderate quality.
In 25 studies including 15 042 participants, there was
low quality evidence of a 13% reduction in incidence of
all-cause diarrhoea (ﬁgure 4; RR 0.87 (0.85 to 0.89)).
Other measures of diarrhoea were consistent with no dif-
ference or with a small reduction in morbidity, including
prevalence of all-cause diarrhoea, hospitalisation due to
all-cause diarrhoea, incidence of severe diarrhoea,
Table 2 Zinc compared with no zinc (all outcomes)
Outcomes Trials People ES (95% CI), fixed effects
Heterogeneity
I
2; χ
2 (p Value)
Zinc vs no zinc
Mortality
All-cause 13 (16%) 138 302 (67%) Risk=0.95 (0.86 to 1.05) 0%; 10.57 (p=0.65)
Due to diarrhoea 4 (5%) 132 321 (64%) Risk=0.95 (0.69 to 1.31) 0%; 0.82 (p=0.84)
Due to LRTI 3 (4%) 132 063 (64%) Risk=0.86 (0.64 to 1.15) 0%; 0.07 (p=0.96)
Due to malaria 2 (3%) 42 818 (21%) Risk=0.90 (0.77 to 1.06) 0%; 0.01 (p=0.94)
Hospitalisation
All-cause 7 (9%) 92 872 (45%) Risk=1.04 (0.97 to 1.11) 44%; 14.41 (p=0.07)
Due to diarrhoea 4 (5%) 74 039 (36%) Risk=1.03 (0.87 to 1.22) 42%; 6.91 (p=0.14)
Due to LRTI 3 (4%) 74 743 (36%) Risk=1.10 (0.93 to 1.30) 0%; 0.35 (p=0.95)
Diarrhoea
Incidence (all-cause) 35 (44%) 15 042 (7%) Risk=0.87 (0.85 to 0.89) 88%; 295.56 (p<0.00001)
Prevalence (all-cause) 13 (16%) 8519 (4%) Rate=0.88 (0.86 to 0.90) 88%; 118.88 (p<0.00001)
Incidence (severe) 5 (6%) 4982 (2%) Risk=0.89 (0.84 to 0.95) 56%; 13.54 (p=0.04)
Incidence (persistent) 7 (9%) 6216 (3%) Risk=0.73 (0.62 to 0.85) 61%; 20.47 (p=0.009)
Prevalence (persistent) 1 (1%) 666 (0%) Rate=0.70 (0.64 to 0.76) 91%; 11.76 (p=0.0006)
LRTI
Incidence 12 (15%) 9610 (5%) Risk=1.00 (0.94 to 1.07) 1%; 17.16 (p=0.44)
Prevalence 3 (4%) 1955 (1%) Rate=1.20 (1.10 to 1.30) 97%; 89.87 (p<0.00001)
Malaria
Incidence 4 (5%) 2407 (1%) Risk=1.05 (0.95 to 1.15) 0%; 2.04 (p=0.84)
Prevalence 1 (1%) 661 (0%) Rate=0.88 (0.47 to 1.64) Not applicable
Growth
Height 51 (64%) 13 669 (7%) SMD=0.09 (0.06 to 0.13) 86%; 407.92 (p<0.00001)
Weight 44 (55%) 12 305 (6%) SMD=0.10 (0.07 to 0.14) 76%; 216.64 (p<0.00001)
Weight-to-height ratio 24 (30%) 7901 (4%) SMD=0.05 (0.01 to 0.10) 20%; 34.96 (p=0.17)
Prevalence of stunting 6 (8%) 3838 (2%) Risk=0. 94 (0.86 to 1.02) 59%; 19.43 (p=0.01)
AEs
Participants with one AE 2 (3%) 850 (0%) SMD=1.13 (1.00 to 1.27) 0%; 0.49 (p=0.78)
Study withdrawal 6 (8%) 4263 (2%) Risk=1.75 (0.93 to 3.32) 21%; 5.07 (p=0.28)
Vomiting (incidence) 5 (6%) 4095 (2%) Risk=1.68 (1.61 to 1.75) 85%; 34.28 (p<0.00001)
Vomiting (prevalence) 4 (5%) 35 192 (17%) Rate=1.29 (1.14 to 1.46) 37%; 6.31 (p=0.18)
Biological indicators
Zn concentration 46 (58%) 9810 (5%) SMD=0.62 (0.58 to 0.67) 91%; 582.45 (p<0.00001)
Zn deficiency (prevalence) 15 (19%) 5434 (3%) Risk=0.49 (0.45 to 0.53) 86%; 144.77 (p<0.00001)
Haemoglobin concentration 27 (34%) 6024 (3%) SMD=−0.05 (−0.10 to 0.00) 45%; 63.96 (p=0.002)
Anaemia (prevalence) 13 (16%) 4287 (2%) Risk=1.00 (0.95 to 1.06) 37%; 28.52 (p=0.05)
Fe concentration 19 (24%) 4474 (2%) SMD=0.07 (0.00 to 0.13) 95%; 480.50 (p<0.00001)
Fe deficiency (prevalence) 10 (13%) 3149 (2%) Risk=0.99 (0.89 to 1.10) 15%; 16.44 (p=0.29)
Cu concentration 11 (14%) 3071 (1%) SMD=−0.22 (−0.29 to 0.14) 68%; 37.47 (p=0.0002)
Cu deficiency (prevalence) 3 (4%) 1337 (1%) Risk=2.64 (1.28 to 5.42) 59%; 4.94 (p=0.08)
AE, adverse event; ES, effect size; LRTI, lower respiratory tract infection; SMD, standardised mean difference.
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diarrhoea and prevalence of persistent diarrhoea.
In 12 trials (9610 participants), there was high-quality
evidence of no effect on LRTI incidence (see online
supplementary appendix 7; RR 1.00 (0.94 to 1.07)). One
trial reported no LRTI in either group.
20 Results for
prevalence were consistent with no difference in respira-
tory morbidity.
Four trials (2407 participants) found moderate quality
evidence that would be consistent with no effect or a
harmful effect on malaria incidence (RR 1.04 (0.94,
1.14)). One study reported no signiﬁcant effect on
malaria prevalence.
Fifty studies reported height for 13 669 participants
(ﬁgure 5). There was moderate quality evidence of a
very small but statistically signiﬁcant increase in linear
growth (SMD 0.09 (0.06 to 0.13)). Results for weight,
weight-to-height ratio and prevalence of stunting were
consistent with no difference or a small effect on
growth.
Forty-six studies reported serum zinc for 9810 partici-
pants. There was evidence of a medium effect (SMD
Table 3 Subgroup analyses
Subgroup Trials People Risk ratio (95% CI), fixed I
2; χ
2 (p Value)
Mortality 13 138 302 0.95 (0.86 to 1.05) 0%; 10.57 (p=0.65)
Iron cosupplementation (I
2=23%; χ
2=1.30, p=0.25)
With iron 4 99 242 0.99 (0.86 to 1.15) 0%; 0.76 (p=0.86)
Without iron 11 64 985 0.89 (0.79 to 1.00) 0%; 9.99 (p=0.44)
Age (I
2=59.8%; χ
2=2.48, p=0.11)
6 months to 1 year 6 29 879 1.06 (0.88 to 1.27) 0%; 2.56 (p=0.77)
1–5 years 8 125 903 0.89 (0.80 to 0.99) 12%; 10.28 (p=0.33)
Dose, mg (I
2=0%; χ
2=2.64, p=0.45)
0–5 2 717 0.72 (0.08 to 6.47) 29%; 1.41 (p=0.23)
5–10 1 274 3.04 (0.32 to 28.90) Not applicable
10–15 11 152 062 0.93 (0.84 to 1.02) 0%; 8.16 (p=0.61)
20 or more 1 2464 0.14 (0.01 to 2.78) Not applicable
Duration, months (I
2=0%; χ
2=1.20, p=0.55)
0–6 2 2817 0.59 (0.07 to 5.15) 47%; 1.88. (p=0.17.)
6–12 7 3898 0.68 (0.37 to 1.25) 4%; 6.23 (p=0.40)
12 or more 6 148 802 0.93 (0.85 to 1.03) 0%; 2.91 (p=0.71)
Formulation (I
2=0%; χ
2=0.54, p=0.91)
Solution 5 3639 0.99 (0.25 to 3.91) 15%; 4.68 (p=0.32)
Pill/tablet 8 149 854 0.93 (0.85 to 1.02) 0%; 6.99 (p=0.43)
Capsule 1 306 0.51 (0.05 to 5.60) Not applicable
Powder 1 1718 0.71 (0.27 to 1.86) Not applicable
Incidence of diarrhoea 35 15 042 0.87 (0.85 to 0.89) 88%; 295.56 (p<0.00001)
Iron cosupplementation (I
2=99%; χ
2=65.11, p<0.00001)
With iron 10 4299 1.00 (0.96 to 1.05) 76%; 37.33 (p<0.00001)
Without iron 22 11 344 0.82 (0.80 to 0.84) 87%; 196.27 (p<0.00001)
Age (I
2=0%; χ
2=0.32, p=0.85)
6 months to 1 year 10 5576 0.88 (0.85 to 0.90) 95%; 252.46 (p<0.00001)
1–5 years 15 8370 0.87 (0.84 to 0.90) 43%; 31.48 (p=0.03)
5–13 years 1 842 0.90 (0.81 to 0.98) Not applicable
Dose, mg (I
2=98%; χ
2=195.69, p<0.00001)
0–5 4 1784 0.95 (0.89 to 1.01) 73%; 22.46 (p=0.001)
5–10 6 2630 0.73 (0.64 to 0.83) 67%; 15.32 (p=0.009)
10–15 11 5452 0.96 (0.92 to 0.99) 69%; 38.39 (p=0.0001)
15–20 2 477 0.61 (0.58 to 0.65) 0%; 0.21 (p<0.00001)
20 or more 6 4931 0.90 (0.87 to 0.94) 75%; 28.17 (p<0.00001)
Duration, months (I
2=0%; χ
2=1.15, p=0.56)
0–6 7 4190 0.89 (0.85 to 0.93) 57%; 16.42 (p=0.02)
6–12 14 8971 0.86 (0.84 to 0.89) 93%; 250.92 (p<0.00001)
12 or more 5 1881 0.88 (0.82 to 0.95) 73%; 29.82 (p=0.0002)
Formulation (I
2=94%; χ
2=51.34, p<0.00001)
Solution 19 10 768 0.84 (0.82 to 0.86) 90%; 236.48 (p<0.00001)
Pill/tablet 3 1696 0.90 (0.81 to 0.99) 5%; 3.15 (p=0.37)
Capsule 1 612 0.78 (0.60 to 1.01) Not applicable
Powder 2 1861 1.04 (0.98 to 1.09) 0%; 0.65 (p=0.42)
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sistently favoured zinc rather than no-intervention, but
they were extremely inconsistent in magnitude, possibly
due to differences in participants and settings
(χ
2=582.45, df=47 (p<0.00001); I
2=91%). Eleven studies
reported serum copper for 3071 participants (1% of par-
ticipants in this review). There was very low-quality evi-
dence of a small reduction in copper (SMD −0.22
(−0.29 to 0.14)); as above, the results were inconsistent
(χ
2=37.47, df=10 (p<0.0002); I
2=68%). There was no evi-
dence of an effect on haemoglobin, prevalence of
anaemia or iron status.
In ﬁve trials (35 192participants), there was high-
quality evidence of increased vomiting (RR 1.29 (1.14 to
1.46)). Two trials reported no adverse events in either
group (ie, supplemented or non-supplemented).
21 22
Results for study withdrawal, participants with one or
more side effects and number of vomiting episodes indi-
cate some short-term side effects; there was no evidence
of serious adverse events.
Effects of zinc plus iron compared with zinc alone
Effects on mortality were not signiﬁcantly different
between subgroups with and without iron (χ
2=1.30,
p=0.25); however, there was no mortality effect in groups
receiving iron (RR 0.99 (0.86 to 1.15)) while the effect
for groups that did not receive iron was nearly signiﬁ-
cant (RR 0.89 (0.79 to 1.00)). Effects on the incidence
of diarrhoea differed between groups (ﬁgure 4;
χ
2=65.11, p<0.00001), with no beneﬁt for the group that
received iron (RR 1.00 (0.96 to 1.05)) and a signiﬁcant
beneﬁt for the group that did not receive iron (RR 0.82
(0.80 to 0.84)). There were signiﬁcant effects with and
without iron cosupplementation on zinc status; these
were greater in studies without iron for serum zinc
(χ
2=27.07, p<0.00001) and prevalence of zinc deﬁciency
(χ
2=34.27, p<0.00001). There were also differences
between these groups of studies for serum ferritin and
serum copper; zinc had no effect in studies with iron
cointervention, but zinc without iron cointervention
reduced ferritin and copper. Overall effects on growth
were small; there was a signiﬁcant difference between
subgroups for height but not weight, and the difference
for weight-to-height ratio favoured the group that
received iron (ie, the opposite of the other results).
There were no signiﬁcant effects in either subgroup for
LRTIs, serum haemoglobin, prevalence of anaemia or
prevalence of iron deﬁciency.
Several trials compared zinc coadministered with iron
versus zinc given alone (see online supplementary
appendix 6). One trial reported no signiﬁcant differ-
ence in all-cause mortality (323 participants; RR 0.33
(0.01 to 8.39)). In ﬁve trials (1530 participants), effects
on incidence of all-cause diarrhoea favoured zinc alone
(RR 1.10 (1.03 to 1.18)). In one trial (399 participants),
effects on prevalence of all-cause diarrhoea favoured
zinc with iron, but this was not signiﬁcant (RR 0.90
(0.79 to 1.06)). Five trials (1329 participants) reported
no difference in height (SMD 0.06 (−0.04 to 0.16)).
Similarly, there was low-quality evidence and mixed
results for other outcomes (table 4).
Additional subgroup analyses
Studies in high-income countries did not evaluate most
outcomes, so we were unable to explore differences in
effect by national income. Effects on weight and
Figure 3 All-cause mortality by age.
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Open Accessweight-to-height ratio were not statistically different, and
there was no evidence of consistent differences in bio-
logical outcomes (see online supplementary appendix 6).
Most studies included stunted and non-stunted chil-
dren, and it was not possible to compare effects between
studies for most outcomes. Differences between groups
were not signiﬁcant for growth, but these would be con-
sistent with larger effects in studies of stunted children.
Age was not signiﬁcantly associated with effects on
mortality or incidence diarrhoea, but results would be
consistent with greater beneﬁts in children over 1 year
of age (ﬁgure 3). Effects on weight were greatest in
studies of older children, and there was a similar pattern
for height, though the largest study of children over
5 years of age included only 804 participants. The effect
of supplementation on zinc deﬁciency was greater in
studies of older children, as was the negative effect on
copper. There was no evidence of consistent differences
in other biological outcomes.
Dose was not signiﬁcantly associated with effects on
mortality, incidence of LRTI, haemoglobin or
weight-to-height ratio. The pattern of results was incon-
sistent for incidence and prevalence of diarrhoea,
height, weight and plasma ferritin (see online supple-
mentary appendix 6). Subgroups were signiﬁcantly dif-
ferent for serum zinc, prevalence of zinc deﬁciency,
prevalence of iron deﬁciency and plasma copper; only
these results are consistent with a dose–response
relationship.
Duration of supplementation was not signiﬁcantly
associated with effects on mortality, incidence of diar-
rhoea, incidence of LRTI, weight-to-height ratio or
prevalence of iron deﬁciency (see online supplementary
appendix 6). There was a signiﬁcant difference for
Figure 4 Incidence of all-cause diarrhoea with and without iron cosupplementation.
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Open Accessprevalence of diarrhoea, but the magnitude of this dif-
ference may not be important. Studies of longer supple-
mentation were associated with greater effects on height;
the pattern of results was not consistent for weight. By
contrast, the largest beneﬁts for biological markers
(serum zinc and prevalence of zinc deﬁciency) were
reported in the shortest studies.
Formulation was associated with differences among
subgroups, though few studies included capsules or
powder. When comparing solution and tablets, differ-
ences were not signiﬁcant for mortality, incidence and
prevalence of diarrhoea; incidence of LRTI; blood
haemoglobin; prevalence of anaemia or prevalence of
iron deﬁciency. There were signiﬁcant differences in the
effects of serum ferritin and serum copper, but only
three studies of each outcome used tablets, and they
were highly heterogeneous. The effects on height,
weight and serum zinc were greater in studies using solu-
tion compared with tablet, but all effects were small (see
online supplementary appendix 6).
Reporting bias
For outcomes included in the summary of ﬁndings table
with 10 or more studies, we also conducted a
trim-and-ﬁll analysis to investigate reporting bias (see
online supplementary appendix 8).
23 There was some
evidence of small study bias—studies were trimmed for
all-cause mortality (1 trimmed) and incidence of
Figure 5 Height.
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trimmed for incidence of LRTI; nor were any trimmed
for height. The adjusted effect for mortality was not
importantly different from the observed effect, but the
observed effect for diarrhoea (RR 0.87 (0.85 to 0.89))
was larger than the adjusted value (RR 0.95 (0.93 to
0.97)).
DISCUSSION
Consistent with previous reviews, this review ﬁnds high-
quality evidence from several large, well-conducted
trials.
571 0We believe that these results suggest zinc sup-
plementation is probably associated with a small reduc-
tion in all-cause mortality for children at risk of
deﬁciency. In interpreting these results, we considered
that the results of this meta-analysis are drawn from 13
trials including almost 140 000 participants. The results
of those studies are statistically consistent, the overall CIs
are relatively small and the balance of probability
favours zinc supplementation rather than placebo. Small
reductions in cause-speciﬁc mortality were consistent
with effects on illness and cause-speciﬁc mortality, and
the results were biologically plausible. Beneﬁts in any
speciﬁc area may be related to the level of deﬁciency;
countries with very high levels of deﬁciency could
expect the largest reductions in mortality as a result of
supplementation.
24 This review also suggests that bene-
ﬁts may not be restricted to young children; there is
some evidence of beneﬁts on secondary outcomes in
trials including children over 5 years of age, but there is
a lack of evidence about the effects on mortality in this
group.
Results for secondary outcomes suggest modest bene-
ﬁts. The main results for diarrhoea morbidity were con-
sistent with previous reviews,
4571 0but an asymmetrical
funnel plot was indicative of small-study bias. After
adjustment, the effect for diarrhoea was halved, and the
reduced estimate was consistent with other critical out-
c o m e si nt h i sr e v i e w .P r e v i o u sr e v i e w sh a v es u g g e s t e db e n e -
ﬁcial effects on respiratory infections
459 –12 and malaria,
10
which this review does not conﬁrm, and also reported vari-
able effects on growth
568 ; this review suggests that pre-
ventive zinc supplementation alone is unlikely to have
large effects on linear growth and morbidity.
Supplementation is associated with increased risk of vomit-
ing, but there is no evidence of lasting adverse effects.
Critical outcomes included data for 2407–138 302 par-
ticipants, so further placebo-controlled trials of
Table 4 Zinc with iron compared with zinc alone (all outcomes)
Outcomes Trials People ES (95% CI), fixed effects
Heterogeneity
I
2; χ
2 (p Value)
All-cause mortality 1 (13%) 323 (17%) Risk=0.33 (0.01 to 8.31) Not applicable
Hospitalisation
All-cause 1 (13%) 399 (21%) Risk=0.92 (0.45 to 1.89) Not applicable
Due to diarrhoea 1 (13%) 399 (21%) Risk=0.99 (0.25 to 3.88) Not applicable
Diarrhoea
Incidence (all-cause) 5 (63%) 1530 (81%) Risk=1.10 (1.03 to 1.18) 76%; 16.92 (p=0.002)
Prevalence (all-cause) 1 (13%) 399 (21%) Rate=0.90 (0.79 to 1.06) Not applicable
Incidence (severe) 1 (13%) 323 (17%) Rate=0.78 (0.59 to 1.04) Not applicable
Lower respiratory tract infection
Incidence 3 (38%) 1065 (56%) Risk=0.93 (0.83 to 1.04) 21%; 2.52 (p=0.28)
Malaria
Incidence 1 (13%) 410 (22%) Rate=0.86 (0.59 to 1.24) Not applicable
Growth
Height 5 (63%) 1517 (80%) SMD=0.06 (−0.04 to 0.16) 0%; 3.54 (p=0.47)
Weight 4 (50%) 910 (48%) SMD=0.12 (−0.01 to 0.25) 0%; 2.29 (p=0.51)
Weight-to-height ratio 4 (50%) 514 (27%) SMD=−0.06 (−0.07 to 0.19) 0%; 1.36 (p=0.71)
Prevalence of stunting 2 (25%) 462 (24%) Risk=0.92 (0.85 to 0.99) 45%; 1.82 (p=0.18)
Adverse events
Study withdrawal 2 (25%) 557 (29%) Risk=1.41 (0.91 to 2.18) 0%; 0.08 (p=0.78)
Biological indicators
Zn concentration 8 (100%) 1337 (70%) SMD=0.16 (0.05 to 0.27) 61%; 17.84 (p=0.01)
Zn deficiency (prevalence) 3 (38%) 350 (18%) Risk=1.42 (0.75 to 2.68) 5%; 2.10 (p=0.35)
Haemoglobin concentration 8 (100%) 1341 (71%) SMD=−0.23 (−0.34 to −0.12) 79%; 33.53 (p<0.0001)
Anaemia (prevalence) 3 (38%) 482 (25%) Risk=0.78 (0.67 to 0.92) 0%; 1.25 (p=0.54)
Fe concentration 6 (75%) 945 (50%) SMD=−1.79 (−1.99 to −1.56) 99%; 927.92 (p<0.00001)
Fe deficiency (prevalence) 2 (25%) 248 (13%) Risk=0.12 (0.04 to 0.32) 87%; 8.00 (p=0.005)
Cu concentration 2 (25%) 353 (19%) SMD=−0.06 (−0.27 to 0.15) 0%; 0.11 (p=0.74)
Effects favour intervention (ie, zinc rather than iron; zinc plus iron rather than zinc alone) when the relative risk is reduced (RR<1) or the
standardised difference is positive (SMD>0).
ES, effect size; Rate, rate ratio; Risk, risk ratio; SMD, standardised mean difference.
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Open Accesspreventive zinc supplementation for young children may
not be necessary. However, subgroup analyses did not
identify an optimal supplementation strategy (ie, dose,
formulation and frequency), and large trials comparing
active interventions could inform clinical guidelines.
Subgroup analyses identify some sources of observed
heterogeneity; however, subgroups that were statistically
different included a large amount of residual heterogen-
eity, which is reﬂected in our judgements about the
quality of the evidence (table 1). Analyses of group-level
data are of limited value for identifying moderators, par-
ticularly in analyses dominated by a few large studies.
Further analyses of individual patient data would be
more conclusive.
Effects on biological indicators were inconsistent
across studies, but large effects on these measures were
not always reﬂected in clinical outcomes.
Supplementation may increase serum zinc, but the mag-
nitude of the effect appears to differ across populations
and interventions. Effects on other micronutrients,
including iron and copper, are uncertain. Researchers
have suggested that iron supplementation may interfere
with the absorption of zinc and, conversely, that zinc
may interfere with iron and copper absorption
25 26;
however, the relationships between these biomarkers
and clinical outcomes (ie, mortality and morbidities)
have not been established.
Subgroup analyses comparing zinc with and without
iron did not resolve uncertainty about the effect of
cosupplementation. Only four studies with iron cosupple-
mentation reported mortality outcomes, and evidence of
outcome reporting bias for diarrhoea incidence leads to
cautious interpretation of differences in this outcome.
There was no evidence that larger doses or increased dur-
ation was associated with increased iron deﬁciency, but
these comparisons are observational and could be
affected by uncontrolled covariates.
Direct comparisons within trials provide the only
experimental evidence about the effects of cosupplemen-
tation with iron. For rare events like mortality, effects of
zinc and iron can only be detected in large studies, so
studies of interaction effects will need to be very large to
detect real differences. Future studies are needed to iden-
tify the main effects and to explore how administration
(ie, separate or combined) affects uptake and costs.
Dietary intake and supplementation have reduced
micronutrient deﬁciencies in Asia, but micronutrient
deﬁciencies remain common.
32 7The prevalence of
micronutrient deﬁciencies is declining in Africa, but the
absolute number of deﬁcient children is increasing.
3
This review suggests that the overall beneﬁts of prevent-
ive zinc supplementation outweigh potential harms in
areas with a high risk of zinc deﬁciency. Further research
is needed to determine if these beneﬁts extend to chil-
dren over 5 years of age. Current estimates suggest that
delivering 10 evidence-based nutrition-speciﬁc interven-
tions, including preventive zinc supplements, could
reduce global mortality in children under 5 years of age
by 15%.
28 To that end, research is needed to identify the
most effective strategies for delivering zinc supplements
to populations in need.
29
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